%0 English Abstract
%T [Chinese guideline on the diagnosis and treatment of thyroid-associated ophthalmopathy (2022)].
%A  
%A  
%A  
%A  
%J Zhonghua Yan Ke Za Zhi
%V 58
%N 9
%D Sep 2022 11
%M 36069085
暂无%R 10.3760/cma.j.cn112142-20220421-00201
%X Thyroid-associated ophthalmopathy (TAO) is an orbital disease closely related to thyroid diseases. TAO has a prolonged course and possibility of blindness and disability. Its diagnosis and treatment can be complex with multiple disciplines involved. To improve the standardized diagnosis and treatment of TAO in China, the Oculoplastic and Orbital Disease Group of Chinese Ophthalmological Society of Chinese Medical Association and the Thyroid Group of Chinese Society of Endocrinology of Chinese Medical Association have jointly drawn up this first clinical guideline in China for TAO by complying with the principles, methods and steps of guideline formation. In this guideline, there are 24 recommendations for the major clinical problems in the diagnosis and treatment of TAO, including the clinical diagnostic criteria, disease staging and grading methods, novel treatment based on the pathogenesis, multi-disciplinary treatment, risk factor control, individualized selection of treatment such as drugs, radiation and surgery, therapeutic efficacy evaluation and critical illness management. This guideline provides instructions for clinicians to carry out relevant clinical and research work.<BR>甲状腺相关眼病（TAO）是一种与甲状腺疾病密切相关的眼眶疾病，病程迁延，可致盲、致残，诊疗过程复杂并涉及多个学科。为提高我国TAO的规范化诊疗水平，中华医学会眼科学分会眼整形眼眶病学组联合中华医学会内分泌学分会甲状腺学组，按照临床诊疗指南制订的指导原则、方法和步骤，针对TAO诊疗中的主要临床问题提出24条推荐意见，主要涉及TAO临床诊断标准，疾病分期、分级方法，基于TAO发病机制的新型治疗方法，TAO的多学科联合管理，危险因素控制，药物、放射、手术等治疗方案的个体化选择以及疗效评估和危重症处理，形成我国首部与TAO诊疗相关的临床指南，以指导临床开展工作。.